Elan share price down
IRISH pharmaceutical company Elan recorded a share price fall on the back of further cases of a rare brain disease in multiple sclerosis patients taking the company's Tysabri.
A total of 42 confirmed cases of progressive multifocal leukoencephalopathy (PML) were reported by March 10.
Of these, just over one in five -- nine cases -- has proven fatal.
Elan's Dublin share price slipped by 4c, or 0.73pc, to €5.46 yesterday, on the back of that news. Tysabri's performance has been good of late -- last year, sales of the drug grew by 30pc.